CARB-X

Combating Antibiotic Resistant Bacteria

Global Accelerator Network

CARB-X BENEFITS — BEYOND THE FUNDING

Therapeutics and Vaccines

Looking for help with your project? CARB-X provides a full range of specialized services, expertise and know-how — in addition to funding and free of charge — to support product development.

CARB-X has teamed up with a network of nine world-class accelerators in five countries to provide a full range of services tailored to the specific needs of product developers. CARB-X funded product developers also get streamlined access to NIAID Preclinical Services and guidance. All services are provided at no cost to the product developer.

Therapeutics and Vaccines expertise (small molecule, microbiome, phage, biologics)

Hit-to-Lead & Lead Optimization	**Scientific advice and guidance**	• Mechanism of Action (MOA) and mode of resistance • Medicinal chemistry planning and execution • *In vitro/ in vivo* exploratory toxicology • Animal efficacy and PK/PD • Genomics, metagenomics, microbiome, bioinformatics • Vaccine development • Facilitation of Contract Research Organization (CRO) services; review of Statement of Work (SOW) and quotations
	NIAID Pre-clinical services — expedited access	• *In vitro* screening • Animal efficacy models – standard and custom • Synthetic route scouting
	Project management support	• Review of Target Product Profiles (TPP) • Design of screening assays and cascades • Development of appropriate project milestones
	Access to materials	• Acquisition of pathogenic bacterial strains • Compound libraries
Preclinical	**Scientific advice and guidance**	• Toxicology study design, data interpretation and issue resolution • Compliance of toxicology studies with GLP regulations • PK/PD study planning • *In vivo* ADMET studies planning • Review of study protocols/reports • Facilitation of CRO services; review of SOWs and quotations
	NIAID Preclinical Services — expedited access	• Animal efficacy models – standard and custom • Safety studies • Compound scale-up
	Chemistry, Manufacturing, and Controls (CMC)	• Guidance on process development, scale up, pilot scale manufacturing and phase appropriate specification setting: Active Pharmaceutical Ingredient (API), Investigational Medicinal Products (IMP), Drug Product (DP) • CMC project plan review and gap analysis (execution, quality and closeout plans) • Advice on reference/working/master cell banks, quality control and release • Review of quality systems, as well as audit findings and remediation plans • Facilitation of CRO services; review of SOWs and quotations
	Clinical planning support	• Trial design, design, protocol, investigator's brochure, informed consent • Potential clinical collaborators • Introductions to Key Opinion Leaders (KOLs)
	Regulatory support and guidance	• Pre-submission package • Regulatory documents (e.g. INDs) • Facilitate Interactions for Informal advice with regulatory bodies in US, Europe, India • Support in formal regulatory interactions

Therapeutics and Vaccines expertise continued on reverse side

Therapeutics and Vaccines expertise (small molecule, microbiome, phage, biologics)

Clinical	**Scientific advice and guidance**	• Adverse events, protocol amendments • Facilitation of CRO services
	Regulatory	• Support in regulatory interactions

Business and operation support

Funding	**Funding strategy support**	• Business development/partnering/licensing • Insight into funding opportunities globally (dilutive and non-dilutive)
	Direct support	• Business plans, deal sheets, messaging, pitch presentations, one-pagers, elevator pitch • Introductions to targeted investment community members • Letter of support
Strategy	**Tailored guidance and support**	• TPP and Commercialization Plan • Development and leveraging of scientific advisory board • Access to experts and KOLs globally • Stewardship and access plans
	Insight into product landscape	• Global unmet medical needs • Governmental plans for antibacterial product development • Different cultures and healthcare settings, including low- and middle-income countries
Physical Space and Facilities	**Lab and/or office space (requires an application)**	• Bangalore, India • Basel, Switzerland • Copenhagen, Denmark • Union, NJ, US

CARB-X Global Accelerator Network

The Global Accelerator Network is a unique source of specialized expertise and know-how in anti-bacterial drug development, diagnostics, vaccines, business and legal strategy, regulatory affairs and other areas essential to accelerating CARB-X's growing portfolio.

BASEL AREA. SWISS · BioInnovation Institute · CLSI California Life Sciences Institute · C-CAMP Centre for Cellular and Molecular Platforms · FIND Because diagnosis matters · DZIF German Center for Infection Research · ILSE Institute for Life Science Entrepreneurship · MassBio Massachusetts Biotechnology Council · RTI International

This fact sheet is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and awards from Wellcome Trust, Germany's Federal Ministry of Education and Research (BMBF), the Global AMR Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC), and the Bill & Melinda Gates Foundation, as administrated by CARB-X. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response or other funders.